Nonacus Galeas Hereditary Plus Panel
Nonacus has launched a 146-gene next-generation sequencing panel to aid the detection of cancers that are caused by inherited genetic mutations. The firm said its Galeas Hereditary Plus panel combines an optimized wet lab workflow with proprietary bioinformatics software and reduces the need for multiplex ligation dependent probe amplification (MLPA) analysis to detect copy number variation mutations. The panel includes results for rare or difficult-to-detect inherited disorders such as Lynch syndrome, pheochromocytoma, and Wilms tumor. According to the UK-based firm, the test is compliant with guidelines from the Association for Molecular Pathology and European Society for Molecular Oncology, and it covers all genes in the UK's National Genomics Test Directory for genetic testing for rare and inherited disorders.